237 related articles for article (PubMed ID: 22329487)
1. Ring A of nukacin ISK-1: a lipid II-binding motif for type-A(II) lantibiotic.
Islam MR; Nishie M; Nagao J; Zendo T; Keller S; Nakayama J; Kohda D; Sahl HG; Sonomoto K
J Am Chem Soc; 2012 Feb; 134(8):3687-90. PubMed ID: 22329487
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial mechanism of lantibiotics.
Islam MR; Nagao J; Zendo T; Sonomoto K
Biochem Soc Trans; 2012 Dec; 40(6):1528-33. PubMed ID: 23176511
[TBL] [Abstract][Full Text] [Related]
3. LiaRS reporter assay: A simple tool to identify lipid II binding moieties in lantibiotic nukacin ISK-1.
Elsayed KM; Islam MR; Abdullah-Al-Mahin ; Nagao JI; Zendo T; Sonomoto K
J Biosci Bioeng; 2017 Mar; 123(3):398-401. PubMed ID: 27856233
[TBL] [Abstract][Full Text] [Related]
4. The mode of action of the lantibiotic lacticin 3147--a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II.
Wiedemann I; Böttiger T; Bonelli RR; Wiese A; Hagge SO; Gutsmann T; Seydel U; Deegan L; Hill C; Ross P; Sahl HG
Mol Microbiol; 2006 Jul; 61(2):285-96. PubMed ID: 16771847
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of essential and variable residues of nukacin ISK-1 by NNK scanning.
Islam MR; Shioya K; Nagao J; Nishie M; Jikuya H; Zendo T; Nakayama J; Sonomoto K
Mol Microbiol; 2009 Jun; 72(6):1438-47. PubMed ID: 19432794
[TBL] [Abstract][Full Text] [Related]
6. Lipid II-based antimicrobial activity of the lantibiotic plantaricin C.
Wiedemann I; Böttiger T; Bonelli RR; Schneider T; Sahl HG; Martínez B
Appl Environ Microbiol; 2006 Apr; 72(4):2809-14. PubMed ID: 16597986
[TBL] [Abstract][Full Text] [Related]
7. Lysine-oriented charges trigger the membrane binding and activity of nukacin ISK-1.
Asaduzzaman SM; Nagao J; Aso Y; Nakayama J; Sonomoto K
Appl Environ Microbiol; 2006 Sep; 72(9):6012-7. PubMed ID: 16957223
[TBL] [Abstract][Full Text] [Related]
8. Interaction of type A lantibiotics with undecaprenol-bound cell envelope precursors.
Müller A; Ulm H; Reder-Christ K; Sahl HG; Schneider T
Microb Drug Resist; 2012 Jun; 18(3):261-70. PubMed ID: 22432708
[TBL] [Abstract][Full Text] [Related]
9. Mapping and identification of the region and secondary structure required for the maturation of the nukacin ISK-1 prepeptide.
Nagao J; Morinaga Y; Islam MR; Asaduzzaman SM; Aso Y; Nakayama J; Sonomoto K
Peptides; 2009 Aug; 30(8):1412-20. PubMed ID: 19481127
[TBL] [Abstract][Full Text] [Related]
10. Lantibiotic engineering: molecular characterization and exploitation of lantibiotic-synthesizing enzymes for peptide engineering.
Nagao J; Aso Y; Shioya K; Nakayama J; Sonomoto K
J Mol Microbiol Biotechnol; 2007; 13(4):235-42. PubMed ID: 17827974
[TBL] [Abstract][Full Text] [Related]
11. Lipid II: a central component in bacterial cell wall synthesis and a target for antibiotics.
de Kruijff B; van Dam V; Breukink E
Prostaglandins Leukot Essent Fatty Acids; 2008; 79(3-5):117-21. PubMed ID: 19008088
[TBL] [Abstract][Full Text] [Related]
12. A novel lantibiotic, nukacin ISK-1, of Staphylococcus warneri ISK-1: cloning of the structural gene and identification of the structure.
Sashihara T; Kimura H; Higuchi T; Adachi A; Matsusaki H; Sonomoto K; Ishizaki A
Biosci Biotechnol Biochem; 2000 Nov; 64(11):2420-8. PubMed ID: 11193411
[TBL] [Abstract][Full Text] [Related]
13. Expanding role of lipid II as a target for lantibiotics.
Martin NI; Breukink E
Future Microbiol; 2007 Oct; 2(5):513-25. PubMed ID: 17927474
[TBL] [Abstract][Full Text] [Related]
14. Microtiter plate bioassay to monitor the interference of antibiotics with the lipid II cycle essential for peptidoglycan biosynthesis.
Burkard M; Stein T
J Microbiol Methods; 2008 Sep; 75(1):70-4. PubMed ID: 18558445
[TBL] [Abstract][Full Text] [Related]
15. Nukacin 3299, a lantibiotic produced by Staphylococcus simulans 3299 identical to nukacin ISK-1.
Ceotto H; Holo H; da Costa KF; Nascimento Jdos S; Salehian Z; Nes IF; Bastos Mdo C
Vet Microbiol; 2010 Nov; 146(1-2):124-31. PubMed ID: 20627619
[TBL] [Abstract][Full Text] [Related]
16. Binding specificity of the lantibiotic-binding immunity protein NukH.
Okuda K; Yanagihara S; Shioya K; Harada Y; Nagao J; Aso Y; Zendo T; Nakayama J; Sonomoto K
Appl Environ Microbiol; 2008 Dec; 74(24):7613-9. PubMed ID: 18978082
[TBL] [Abstract][Full Text] [Related]
17. Enhanced production of nukacin D13E in Lactococcus lactis NZ9000 by the additional expression of immunity genes.
Puramattathu TV; Islam MR; Nishie M; Yanagihara S; Nagao J; Okuda K; Zendo T; Nakayama J; Sonomoto K
Appl Microbiol Biotechnol; 2012 Jan; 93(2):671-8. PubMed ID: 21904816
[TBL] [Abstract][Full Text] [Related]
18. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II.
Hasper HE; Kramer NE; Smith JL; Hillman JD; Zachariah C; Kuipers OP; de Kruijff B; Breukink E
Science; 2006 Sep; 313(5793):1636-7. PubMed ID: 16973881
[TBL] [Abstract][Full Text] [Related]
19. Cooperative transport between NukFEG and NukH in immunity against the lantibiotic nukacin ISK-1 produced by Staphylococcus warneri ISK-1.
Okuda K; Aso Y; Nakayama J; Sonomoto K
J Bacteriol; 2008 Jan; 190(1):356-62. PubMed ID: 17951378
[TBL] [Abstract][Full Text] [Related]
20. Description of complete DNA sequence of two plasmids from the nukacin ISK-1 producer, Staphylococcus warneri ISK-1.
Aso Y; Koga H; Sashihara T; Nagao J; Kanemasa Y; Nakayama J; Sonomoto K
Plasmid; 2005 Mar; 53(2):164-78. PubMed ID: 15737403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
